Drawing for Serial No. 79406335

USPTO serial 79406335

Serial No. 79406335

Reviewed by CopyMark Law Group

Reg. 7877178Status 700Registered
Filing date
Status date
Registration date
Aug 5, 2025
Examiner
PORTARO, ALEXANDRA J
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79406335?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Stephen B. Samlan

Stephen B. Samlan Knechtel, Demeur & Samlan525 W Monroe Streeet Suite 2360Chicago, IL 60661United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and drugs for the treatment of respiratory disorders; pharmaceutical preparations and drugs for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical preparations and drugs for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); pharmaceutical preparations and drugs namely bronchodilators and anti-asthma preparations; pharmaceutical preparations and drugs for the treatment of osteogenesis imperfecta (OI) (brittle bone syndrome); pharmaceutical preparations and drugs to improve bone density and treat bone weakness; pharmaceutical preparations and drugs for the treatment of bone-related diseases; pharmaceutical preparations and drugs for the treatment of bone disorders associated with low bone formation, low bone mineral density, low bone mineral content, low bone mass, or low bone strength; pharmaceutical preparations and drugs for the treatment of diseases or disorders associated with collagen mutations; pharmaceutical preparations and drugs for the treatment of obesity; pharmaceutical preparations and drugs for treating testosterone levels; pharmaceutical preparations and drugs namely aromatase inhibitors (AIs); pharmaceutical preparations and drugs for treating hypogonadotrophic hypogonadism (HH); antibiotics; pharmaceutical preparations and drugs for the treatment of diseases mediated by antitrypsin deficiency (AATD); pharmaceutical preparations and drugs for the treatment of respiratory diseases; pharmaceutical preparations and drugs for the treatment or prophylaxis of inflammatory diseases and conditions; pharmaceutical preparations and drugs for the treatment or prevention of a symptom or complication attributable of a SARS-COV infection; pharmaceutical preparations and drugs for the treatment of COVID-19; pharmaceutical preparations and drugs for the treatment or prevention of fibrosis; pharmaceutical preparations and drugs for the treatment or prevention of graft rejection; pharmaceutical preparations and drugs for the treatment or prevention of graft versus host disease (GVHD); pharmaceutical preparations and drugs for the treatment or prevention of bronchiolitis obliterans syndrome (BOS); pharmaceutical preparations and drugs for the treatment of cancer; pharmaceutical preparations and drugs for the treatment of checkpoint inhibitor naïve cancer; pharmaceutical preparations and drugs for the treatment of cervical cancer; pharmaceutical preparations and drugs for the treatment of breast cancer; pharmaceutical preparations and drugs for the treatment of ovarian cancer; pharmaceutical preparations and drugs for the treatment of clear cell ovarian cancer; pharmaceutical preparations and drugs for the treatment of sarcoma; pharmaceutical preparations and drugs for the treatment of soft tissue sarcoma; pharmaceutical preparations and drugs for the treatment of de-differentiated liposarcoma sarcoma; pharmaceutical preparations and drugs for the treatment of germ cell tumours; pharmaceutical preparations and drugs for the treatment of testicular germ cell tumours; pharmaceutical preparations and drugs for the treatment of uveal melanomas; pharmaceutical preparations and drugs for the treatment of cancers with a high tumour mutational burden (TMB); pharmaceutical preparations and drugs for the treatment of microsatellite stable cancer; pharmaceutical preparations and drugs for the treatment of endometrial cancer; pharmaceutical preparations and drugs for the treatment of PVR positive cancer; pharmaceutical preparations and drugs for the treatment of TIGIT positive cancer; pharmaceutical preparations and drugs for the treatment of PD-L1 negative cancer; pharmaceutical preparations and drugs for the treatment of CD226 positive cancer; pharmaceutical preparations and drugs for the treatment of CD8 positive cancer; pharmaceutical preparations and drugs for the treatment of cancer involving reducing Tregs and promoting myeloid cell activation.ACTIVE—
042Medical and pharmaceutical research services; scientific research for medical purposes in the field/for the treatment of respiratory disorders, chronic obstructive pulmonary disease (COPD), acute exacerbations of chronic obstructive pulmonary disease (AECOPD), bronchodilators and anti-asthma preparations, osteogenesis imperfecta (OI) (brittle bone syndrome), bone density, bone weakness, bone-related diseases, bone disorders associated with low bone formation, low bone mineral density, low bone mineral content, low bone mass, or low bone strength, diseases or disorders associated with collagen mutations, obesity, testosterone levels, aromatase inhibitors (AIs), hypogonadotrophic hypogonadism (HH), antibiotics, diseases mediated by antitrypsin deficiency (AATD), respiratory diseases, inflammatory diseases and conditions, SARS-COV infections, COVID-19, fibrosis, graft rejection, graft versus host disease (GVHD), bronchiolitis obliterans syndrome (BOS), cancer, checkpoint inhibitor naïve cancer, cervical cancer, breast cancer, ovarian cancer, clear cell ovarian cancer, sarcoma, soft tissue sarcoma, de-differentiated liposarcoma sarcoma, germ cell tumours, testicular germ cell tumours, uveal melanomas, cancers with a high tumour mutational burden (TMB), microsatellite stable cancer, endometrial cancer, PVR positive cancer, TIGIT positive cancer, PD-L1 negative cancer, CD226 positive cancer, CD8 positive cancer, cancer involving reducing Tregs and promoting myeloid cell activation; medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information, advisory and consultancy services relating to all the aforesaid services.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 26, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 9, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 9, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Mar 5, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 15, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 15, 2026FIMPFINAL DISPOSITION PROCESSED—
Nov 5, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 5, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 5, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 17, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 17, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 11, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 18, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 31, 2025DOCKASSIGNED TO EXAMINER—
Mar 27, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 27, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 27, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 5, 2025RFNTREFUSAL PROCESSED BY IB—
Dec 15, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 15, 2024RFRRREFUSAL PROCESSED BY MPU—
Dec 1, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 29, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 4, 2024DOCKASSIGNED TO EXAMINER—
Oct 11, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 11, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 10, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance